ArticleFrontiers in behavioral neuroscience2025
Chronic 17β-estradiol treatment improves negative valence, anhedonic profile, and social interactions in ovariectomized, middle-aged female rats.
Article in Frontiers in behavioral neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Women experience depression at nearly 2-fold higher rates than men, with middle-age during the menopausal transition being particularly vulnerable. Preclinical studies commonly focus on young adult or aged subjects and/or rely upon a few behavioral tasks. Given the highly variable and heterogenous nature of depression, the current study implemented a behavioral battery to assess whether estradiol (E2, endogenously expressed in women and rats) would improve depressive measures using the Research Domain Criteria (RDoC) for negative valence, anhedonia, sociability, and anxiety in early middle-aged, ovariectomized (OVX) female rats. F344-cdf rats were OVX and injected daily with E2 (3 μg/ml, or oil). Behavioral testing began after 14 days of injections, which continued throughout the study. E2 improved the depressive profile when using a composite metric for negative valence (immobility on the forced swim task, FST), anhedonia (duration to initiate grooming following sucrose splash and latency to initiate grooming with sucrose), sociability (time interacting toward a novel conspecific), and novelty-induced anxiety (time spent investigating marbles). Interestingly, FST immobility significantly and positively correlated with sucrose preference to show they were opposingly related: higher immobility on FST corresponded to more sucrose ingested. Also, time spent in a chamber with a novel conspecific was less informative than time directed at the conspecific. Other tasks, such as the marble bury test showed some hoarding behavior. These nuances revealed difficulties in assessing behaviors within and across studies, but overall showed that E2 improved the depressive-like syndrome (DLS) in middle-aged females based upon the RDoC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.